What Gensciences does

Gensciences (晟斯生物), legally Jiangsu Gensciences Inc. (江苏晟斯生物制药有限公司), is a privately-held clinical-stage biopharmaceutical company founded in 2019 and headquartered in Nantong, Jiangsu Province, China. The company is organized across four wholly-owned subsidiaries: Jiangsu (manufacturing), Beijing Gensciences Inc. (北京基科晟斯医药技术有限公司, R&D in Daxing District), Zhengzhou Gensciences Inc. (郑州晟斯生物科技有限公司, R&D in the Zhengzhou Airport Economy District), and Shanghai Gensciences Inc. (晟斯（上海）生物制药有限公司 / 上海晟斯润康生物技术有限公司, production in Pudong New Area). The firm specializes in long-acting recombinant coagulation factor products for the treatment of hemophilia, addressing an estimated 140,000 hemophilia patients in China of whom 80-85% have hemophilia A (factor VIII deficiency), 15-20% have hemophilia B, and a smaller subpopulation have developed inhibitors against replacement therapy.

Gensciences' pipeline is built on three technological platforms: PEGylated and Fc-fusion recombinant coagulation factor VIII (lead candidates FRSW117 and FRSW107), FVIII-mimetic bispecific antibodies (SS315), and single-dose activated factor VII therapies for inhibitor patients (SS109). FRSW117, an ultra-long-acting PEGylated recombinant human coagulation factor VIII-Fc fusion protein designed for once-weekly dosing, received FDA Orphan Drug Designation in September 2024. FRSW107 entered Phase III clinical trials in December 2023 with the same once-weekly dosing regimen. SS315 has demonstrated preclinical and Phase I hemostatic efficacy as a novel FVIII mimetic, while SS109 is in Phase I evaluation for hemophilia A/B patients with inhibitors. The firm reaches clinicians and KOLs primarily through peer-reviewed publications, ISTH conference presentations, and guideline contributions rather than mass-market commercial channels.

The company is pre-revenue. It has funded development through a Series A round of approximately $123.6 million in March 2021 (led by Haitong Kaiyuan Investment with EFung Capital, Huarong Rongde Asset Management, Hygeia Capital, IDG Capital, and New Alliance Capital), a subsequent round in 2024 with Tencent and ZJ Innopark, and a strategic in-licensing partnership with Denmark's ALK-Abello announced in 2025 that generated an upfront payment and positions Gensciences as a Chinese-market commercialization partner for foreign biopharma assets. Pricing is not publicly disclosed, consistent with the prescription biopharmaceutical model where reimbursement and procurement prices are negotiated post-NMPA approval. Ownership, board composition, and executive compensation are not disclosed in available sources, and the leadership table contains dual CEO listings (Haoyue Hu and Dr. Wang Yali) that the data does not reconcile.

Name

Gensciences

Legal name

Jiangsu Gensciences Inc. (江苏晟斯生物制药有限公司)

Website

https://gensciences.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

251–500 employees

Short description

Gensciences (晟斯生物) is a privately-held, clinical-stage Chinese biopharmaceutical company developing long-acting recombinant coagulation factors, bispecific antibodies, and bypass therapies to treat hemophilia A, B, and inhibitor patients in China and globally.

Ownership category

akta.pro rank

Product category

Hemophilia Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics) (HLAAAAAL)

akta.pro secondary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Coagulation factor therapy
• Hemophilia treatment drugs
• Recombinant protein therapeutics
• Bispecific antibody therapy
• Long-acting biologics

Headquarters

HQ city

Nantong

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Marketing channels2 records

Core offering

Gensciences is a clinical-stage Chinese biopharmaceutical company developing long-acting recombinant coagulation factor therapies for hemophilia treatment. Its portfolio spans FRSW117 (PEGylated factor VIII-Fc fusion protein with FDA Orphan Drug Designation), FRSW107 (extended half-life factor VIII in Phase III), SS109 (inhibitor-bypassing therapy in Phase I), and SS315 (FVIII-mimetic bispecific antibody), enabling once-weekly dosing across hemophilia A, B, and inhibitor populations.

Product overview

Gensciences is a biopharmaceutical company specializing in the development of long-acting coagulation factor products for hemophilia treatment. The company's product portfolio consists of multiple drug candidates: FRSW117 (PEGylated factor VIII-Fc fusion protein, FDA Orphan Drug Designation), FRSW107 (extended half-life factor VIII, Phase III), SS109 (for hemophilia A/B patients with inhibitors, Phase I), and SS315 (bispecific antibody). These products address hemophilia A (factor VIII deficiency, 80-85% of patients), hemophilia B (factor IX deficiency, 15-20%), and hemophilia with inhibitors (requiring activated factor VII therapy). The company operates from multiple locations in China including Jiangsu (manufacturing), Beijing (R&D), Zhengzhou (R&D), and Shanghai (production).

Differentiator

Problem solved

Functional benefit

Products and services

• FRSW117 Once-a-week ultra-long-acting PEGylated recombinant human coagulation factor VIII-Fc fusion protein for hemophilia A treatment; received FDA Orphan Drug Designation. Designed to reduce treatment burden from multiple weekly injections to a single weekly dose for patients with factor VIII deficiency.
• FRSW107 Extended half-life factor VIII Fc fusion protein for severe hemophilia A; currently in Phase III clinical development with once-weekly dosing regimen to reduce injection frequency and improve prophylactic compliance.
• SS109 Investigational single-dose therapy for hemophilia A/B patients who have developed inhibitors (antibodies) against factor VIII or IX replacement therapy, bypassing standard replacement treatment.
• SS315 Novel FVIII-mimetic bispecific antibody for treatment of hemophilia A without inhibitors, demonstrating in vitro and in vivo hemostatic efficacy in preclinical and Phase I studies.
• Long-Acting Coagulation Factors Portfolio Comprehensive suite of long-acting coagulation factor products covering hemophilia A (factor VIII), hemophilia B (factor IX), and hemophilia with inhibitors (activated factor VII), addressing the major hemophilia indications with extended dosing intervals.

Quantifiable outcome

• Approximately 140,000 hemophilia patients in China with 80-85% being hemophilia A

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• ALK-AbellocoreStrategic or Co-development Partner · 1 January 2025Strategic partnership for Chinese market collaboration. ALK-Abello reported an upfront payment from a new Chinese partnership with GenSci as part of their 2025 annual report. The partnership involves GenSci providing access to the Chinese market for ALK's products.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Roche (Hemlibra/emicizumab): Roche's Hemlibra (emicizumab) is the established FVIII-mimetic bispecific antibody for hemophilia A and the direct global benchmark for Gensciences' SS315 candidate. Both companies target hemophilia A with novel antibody architectures, addressing inhibitor and non-inhibitor patients.
• Sanofi (Eloctate/Altuviiio, Eloctate/Factor VIII Fc fusion): Sanofi markets Eloctate (efmoroctocog alfa, Fc fusion recombinant FVIII) and Altuviiio (efanesoctocog alfa), the most direct technological analogs to Gensciences' FRSW117/FRSW107 PEGylated Fc-fusion long-acting FVIII programs. They compete in the same regulatory, mechanism, and dosing-duration category.
• Takeda (Adynovate): Takeda's Adynovate (PEGylated recombinant FVIII, rurioctocog alfa pegol) is the prototype PEGylated long-acting FVIII that FRSW117's architecture most directly emulates, competing head-to-head on dosing interval (twice-weekly) and prophylactic efficacy in hemophilia A.
• Novo Nordisk (Esperoct, NovoEight): Novo Nordisk markets Esperoct (turoctocog alfa pegol), a PEGylated long-acting FVIII with extended half-life, directly comparable to Gensciences' lead hemophilia A assets. Both target prophylaxis-driven outcomes and compete for global and China-market share.
• Bayer (Kovaltry, Jivi): Bayer's Jivi (damoctocog alfa pegol) is a PEGylated recombinant B-domain-deleted FVIII with extended dosing intervals for hemophilia A, providing direct competition to Gensciences' FRSW117 in the long-acting FVIII category.
• CSL Behring (Idelvion, Afstyla): CSL Behring markets Idelvion (albumin-fusion recombinant FIX) for hemophilia B and Afstyla for hemophilia A, representing the same long-acting recombinant coagulation factor franchise strategy as Gensciences' portfolio.

Broad incumbents

• Pfizer (BeneFIX, ReFacto): Pfizer markets BeneFIX (recombinant FIX) for hemophilia B and ReFacto (moroctocog alfa) for hemophilia A as part of its broader rare disease portfolio. While not the longest-acting options, they represent established standard-of-care comparators in the hemophilia recombinant factor category.

Emerging players

• BioMarin Pharmaceutical (Roctavian): BioMarin's Roctavian (valoctocogene roxaparvovec) is the first FDA-approved AAV gene therapy for hemophilia A and represents a potential curative disruption to the chronic recombinant FVIII replacement market Gensciences targets. As an adjacent modality addressing the same patient population, it is a key strategic threat.
• uniQure (etranacogene dezaparvovec): uniQure's hemophilia B gene therapy (etranacogene dezaparvovec, partnered with CSL Behring as Hemgenix) is the first FDA-approved gene therapy for hemophilia B. It competes with Gensciences' planned hemophilia B franchise by offering a one-time curative alternative to chronic recombinant FIX replacement.

Regional players

• GC Pharma (Green Cross): GC Pharma markets GreenGene F (recombinant FVIII) and other coagulation factor products primarily in Asian markets including Korea and emerging geographies. As an Asia-based recombinant coagulation factor competitor, it provides a relevant regional benchmark for Gensciences' China-focused franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gensciences